c15-149: A phase 1b study of the oral CDK4/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration resistant prostate cancer (mCRPC)—A prostate cancer clinical trials consortium study.

Catriona Lewis,David C. Smith,Benedito A. Carneiro,Charles J. Ryan,Tammy J. Rodvelt,Mina Lee,Terence W. Friedlander,Amy M. Lin,Won Kim,Brigid Miralda,Gregory Campbell,Rahul Aggarwal

c15-149: A phase 1b study of the oral CDK4/6 inhibitor ribociclib in combination with docetaxel plus prednisone in metastatic castration resistant prostate cancer (mCRPC)—A prostate cancer clinical trials consortium study.

2018

Catriona Lewis
David C. Smith
Benedito A. Carneiro
Charles J. Ryan
Tammy J. Rodvelt
Mina Lee
Terence W. Friedlander
Amy M. Lin
Won Kim
Brigid Miralda
Gregory Campbell
Rahul Aggarwal

e17028Background: Ribociclib is a potent and selective cyclin-dependent kinase (CDK) 4/6 inhibitor with significant pre-clinical activity in enzalutamide-resistant prostate cancer cell lines. Prior...

Keywords:

Clinical trial
Prostate cancer
Ribociclib
Cancer research
Castration
Prednisone
Physical therapy
Medicine
Docetaxel
Oncology
Cyclin-dependent kinase
castration resistant
Internal medicine
Kinase
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations